Piao W, Li L, Saxena V, Iyyathurai J, Lakhan R, Zhang Y, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration. Nat Commun. 2022;13:2176 pubmed publisher

El Sayes N, Walsh S, Vito A, Reihani A, Ask K, Wan Y, et al. IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity. Mol Ther Oncolytics. 2022;25:16-30 pubmed publisher

Alping P, Burman J, Lycke J, Frisell T, Piehl F. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021;96:e1574-e1584 pubmed publisher

Furtado R, Chorro L, Zimmerman N, Guillen E, Spaulding E, Chin S, et al. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses. Front Immunol. 2020;11:576743 pubmed publisher

Li Z, Zhang H, Huang Y, Huang J, Sun P, Zhou N, et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun. 2020;11:3806 pubmed publisher

Zheng D, Gao F, Cheng Q, Bao P, Dong X, Fan J, et al. A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy. Nat Commun. 2020;11:1985 pubmed publisher

Theivanthiran B, Evans K, Devito N, Plebanek M, Sturdivant M, Wachsmuth L, et al. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy. J Clin Invest. 2020;130:2570-2586 pubmed publisher

Liu Z, Wen J, Wu C, Hu C, Wang J, Bao Q, et al. MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma. Aging (Albany NY). 2020;12:1213-1236 pubmed publisher

Benechet A, De Simone G, Di Lucia P, Cilenti F, Barbiera G, Le Bert N, et al. Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature. 2019;574:200-205 pubmed publisher

Rosenzweig N, Dvir Szternfeld R, Tsitsou Kampeli A, Keren Shaul H, Ben Yehuda H, Weill Raynal P, et al. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun. 2019;10:465 pubmed publisher

Tang H, Liang Y, Anders R, Taube J, Qiu X, Mulgaonkar A, et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J Clin Invest. 2018;128:580-588 pubmed publisher

Vardhana S, Hwee M, Berisa M, Wells D, Yost K, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;: pubmed publisher

Peterson M, Murphy S, Lainson J, Zhang J, Shen L, Diehnelt C, et al. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model. BMC Immunol. 2020;21:25 pubmed publisher

Yamauchi T, Hoki T, Oba T, Saito H, Attwood K, Sabel M, et al. CX3CR1-CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. JCI Insight. 2020;5: pubmed publisher

Brenner E, Schörg B, Ahmetlić F, Wieder T, Hilke F, Simon N, et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun. 2020;11:1335 pubmed publisher

Long Y, Tao H, Karachi A, Grippin A, Jin L, Chang Y, et al. Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Res. 2020;80:499-509 pubmed publisher

Dheilly E, Majocchi S, Moine V, Didelot G, Broyer L, Calloud S, et al. Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity. Antibodies (Basel). 2018;7: pubmed publisher

Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, et al. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nat Commun. 2019;10:3251 pubmed publisher

Konen J, Rodriguez B, Fradette J, Gibson L, Davis D, Minelli R, et al. Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer. Cancers (Basel). 2019;11: pubmed publisher

Poggio M, Hu T, Pai C, Chu B, BELAIR C, Chang A, et al. Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. Cell. 2019;177:414-427.e13 pubmed publisher

Roux C, Jafari S, Shinde R, Duncan G, Cescon D, Silvester J, et al. Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proc Natl Acad Sci U S A. 2019;: pubmed publisher

Blair A, Kleponis J, Thomas D, Muth S, Murphy A, Kim V, et al. IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma. J Clin Invest. 2019;129:1742-1755 pubmed publisher

. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018;6:114 pubmed publisher

Wu A, Wu Q, Deng Y, Liu Y, Lu J, Liu L, et al. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion. EMBO J. 2019;38: pubmed publisher

Tosello Boari J, Araujo Furlan C, Fiocca Vernengo F, Rodríguez C, Ramello M, Amezcua Vesely M, et al. IL-17RA-Signaling Modulates CD8+ T Cell Survival and Exhaustion During Trypanosoma cruzi Infection. Front Immunol. 2018;9:2347 pubmed publisher

Grasselly C, Denis M, Bourguignon A, Talhi N, Mathé D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100 pubmed publisher

Badamchi Zadeh A, Moynihan K, Larocca R, Aid M, Provine N, Iampietro M, et al. Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol. 2018;201:2744-2752 pubmed publisher

Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt F, Liniany L, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247-263.e7 pubmed publisher

Arnold I, Artola Borán M, Tallón de Lara P, Kyburz A, Taube C, OTTEMANN K, et al. Eosinophils suppress Th1 responses and restrict bacterially induced gastrointestinal inflammation. J Exp Med. 2018;215:2055-2072 pubmed publisher

Splitt S, Souza S, Valentine K, Castellanos B, Curd A, Hoyer K, et al. PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii. Infect Immun. 2018;86: pubmed publisher

Choi J, Beaino W, Fecek R, Fabian K, Laymon C, Kurland B, et al. Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. J Nucl Med. 2018;59:1843-1849 pubmed publisher

Takeda Y, Yoshida S, Takashima K, Ishii Mugikura N, Shime H, Seya T, et al. Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. Cancer Sci. 2018;109:2119-2129 pubmed publisher

Wu C, Ning H, Liu M, Lin J, Luo S, Zhu W, et al. Spleen mediates a distinct hematopoietic progenitor response supporting tumor-promoting myelopoiesis. J Clin Invest. 2018;128:3425-3438 pubmed publisher

Xiao W, Klement J, Lu C, Ibrahim M, Liu K. IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. J Immunol. 2018;201:264-277 pubmed publisher

Orecchioni S, Talarico G, Labanca V, Calleri A, Mancuso P, Bertolini F. Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. Br J Cancer. 2018;118:1329-1336 pubmed publisher

Jeon S, Rowe A, Carroll K, Harvey S, Hendricks R. PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1-Infected Corneas. J Immunol. 2018;200:3711-3719 pubmed publisher

Takeda Y, Azuma M, Funami K, Shime H, Matsumoto M, Seya T. Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a Mycoplasma fermentans Lipopeptide. Front Immunol. 2018;9:496 pubmed publisher

Hailemichael Y, Woods A, Fu T, He Q, Nielsen M, Hasan F, et al. Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018;128:1338-1354 pubmed publisher

Zheng F, Dang J, Zha H, Zhang B, Lin M, Cheng F. PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells. Biomed Res Int. 2017;2017:1293201 pubmed publisher

Ibrahim M, Scozzi D, Toth K, Ponti D, Kreisel D, Menna C, et al. Naive CD4+ T Cells Carrying a TLR2 Agonist Overcome TGF-β-Mediated Tumor Immune Evasion. J Immunol. 2018;200:847-856 pubmed publisher

Huffaker T, Lee S, Tang W, Wallace J, Alexander M, Runtsch M, et al. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem. 2017;292:18530-18541 pubmed publisher

Teigler J, Zelinskyy G, Eller M, Bolton D, Marovich M, Gordon A, et al. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection. J Virol. 2017;91: pubmed publisher

Grinberg Bleyer Y, Oh H, Desrichard A, Bhatt D, Caron R, Chan T, et al. NF-?B c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell. 2017;170:1096-1108.e13 pubmed publisher

Goel S, Decristo M, Watt A, BrinJones H, Sceneay J, Li B, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471-475 pubmed publisher

Davis R, Moore E, Clavijo P, Friedman J, Cash H, Chen Z, et al. Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K?/?. Cancer Res. 2017;77:2607-2619 pubmed publisher

Xiang B, Baybutt T, Berman Booty L, Magee M, Waldman S, Alexeev V, et al. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol. 2017;198:3507-3514 pubmed publisher

Mognol G, Spreafico R, Wong V, Scott Browne J, Togher S, Hoffmann A, et al. Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells. Proc Natl Acad Sci U S A. 2017;114:E2776-E2785 pubmed publisher

Sung S, Ge Y, Dai C, Wang H, Fu S, Sharma R, et al. Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice. J Immunol. 2017;198:2589-2601 pubmed publisher

Kim H, Kwon K, Kim W, Shin S. Virulence-dependent induction of interleukin-10-producing-tolerogenic dendritic cells by Mycobacterium tuberculosis impedes optimal T helper type 1 proliferation. Immunology. 2017;151:177-190 pubmed publisher

Spitzer M, Carmi Y, Reticker Flynn N, Kwek S, Madhireddy D, Martins M, et al. Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502.e15 pubmed publisher

Daley D, Zambirinis C, Seifert L, Akkad N, Mohan N, Werba G, et al. ?? T Cells Support Pancreatic Oncogenesis by Restraining ?? T Cell Activation. Cell. 2016;166:1485-1499.e15 pubmed publisher

Aloulou M, Carr E, Gador M, Bignon A, Liblau R, Fazilleau N, et al. Follicular regulatory T cells can be specific for the immunizing antigen and derive from naive T cells. Nat Commun. 2016;7:10579 pubmed publisher

Kim J, Jeong Ryu S, Oh K, Ju J, Yeong Jeon J, Nam G, et al. Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help. Nat Commun. 2015;6:7994 pubmed publisher

Ngiow S, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, et al. A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Cancer Res. 2015;75:3800-11 pubmed publisher

Tkachev V, Goodell S, Opipari A, Hao L, Franchi L, Glick G, et al. Programmed death-1 controls T cell survival by regulating oxidative metabolism. J Immunol. 2015;194:5789-800 pubmed publisher

Zander R, Obeng Adjei N, Guthmiller J, Kulu D, Li J, Ongoiba A, et al. PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe. 2015;17:628-41 pubmed publisher

Twyman Saint Victor C, Rech A, Maity A, Rengan R, Pauken K, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373-7 pubmed publisher

Jaworska K, Ratajczak J, Huang L, Whalen K, Yang M, Stevens B, et al. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194:325-33 pubmed publisher

Dolina J, Braciale T, Hahn Y. Liver-primed CD8+ T cells suppress antiviral adaptive immunity through galectin-9-independent T-cell immunoglobulin and mucin 3 engagement of high-mobility group box 1 in mice. Hepatology. 2014;59:1351-65 pubmed publisher

Yang X, Zhang X, Fu M, Weichselbaum R, Gajewski T, Guo Y, et al. Targeting the tumor microenvironment with interferon-? bridges innate and adaptive immune responses. Cancer Cell. 2014;25:37-48 pubmed publisher

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum R, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687-95 pubmed publisher

Dietze K, Zelinskyy G, Liu J, Kretzmer F, Schimmer S, Dittmer U. Combining regulatory T cell depletion and inhibitory receptor blockade improves reactivation of exhausted virus-specific CD8+ T cells and efficiently reduces chronic retroviral loads. PLoS Pathog. 2013;9:e1003798 pubmed publisher

Rutigliano J, Sharma S, Morris M, Oguin T, McClaren J, Doherty P, et al. Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells. J Virol. 2014;88:1636-51 pubmed publisher

Willimsky G, Schmidt K, Loddenkemper C, Gellermann J, Blankenstein T. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J Clin Invest. 2013;123:1032-43 pubmed publisher

Hafalla J, Claser C, Couper K, Grau G, Renia L, de Souza J, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Pathog. 2012;8:e1002504 pubmed publisher

Riella L, Watanabe T, Sage P, Yang J, Yeung M, Azzi J, et al. Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. Am J Transplant. 2011;11:832-40 pubmed publisher

Zhang L, Gajewski T, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545-52 pubmed publisher